"It pretty much has been adopted around the world so that about 80% of men who are diagnosed with low-risk prostate cancer go on active surveillance. In Sweden, it's about 80%. That's considered the goal. But the United States has been slow in adopting this," says William J. Catalona, MD.
In this video, William J. Catalona, MD, highlights the lag in active surveillance rates seen in the United States. Catalona is a professor of urology at Northwestern University in Chicago, Illinois.
Video Transcript:
When it started out, it was mainly for old men with a smidgen of low-risk prostate cancer. But it became more popular and more younger and healthier men chose active surveillance. It pretty much has been adopted around the world so that about 80% of men who are diagnosed with low-risk prostate cancer go on active surveillance. In Sweden, it's about 80%. That's considered the goal. But the United States has been slow in adopting this. Before 2010, it was only a very small percentage of patients who were put on active surveillance. Over the years up until the latest paper published on this, it's only about just under 60%. They still would like to bring it up to 80% for the United States. In the studies that have been done, and looking at the science of this, they found that if they look at groups practicing urology, or individual urologists, some of them put 100% of their men on active surveillance and some put 0% on, and you have everything in between. It's human behavior that not every urologist is going to be an angel and put 80% of the men on active surveillance. If all urologists were angels, we wouldn't need these guidelines; they would all do the right thing. The people around the world say this is predominantly United States problem. They say that perhaps some of the American urologists are driven by financial gain by treating everybody with radiation or treating everybody was surgery, even though they have what appears to be a minimal disease.
This transcription has been edited for clarity.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.